Simultaneously, ROS significantly increases PD-L1 mRNA levels by accelerating the expression of the transcription factor NRF2.ERK2 inhibitors in combination with anti-PD-L1 antibodies significantly inhibit CRC development (62). Here, CD274 is linked to colorectal carcinoma.